profit from every $100 of sales.
$0$100
Bristol-Myers Squibb Company Ce
$0.12-13.00% today
+327.4% in 1 year
1-year low $0.021-year high $0.23
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Bristol-Myers Squibb Company Ce vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bristol-Myers Squibb Company Ce | No profit yet | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
AI analysis
An AI analyst reads Bristol-Myers Squibb Company Ce's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- 0.0×
- –
- –
- –
- –
- –
Profitability
- 96.2%
- 34.0%
- 26.5%
- 40.6%
- 13.6%
- 5.2%
- 61.9%
- 11.4%
- 16.5%
- 37.1%
Growth
- +1.0%
- +2.4%
- −7.9%
- –
- −2.2%
Financial health
- 2.6×
- 3.29
- 57.1%
- 7.0×
- 2.23
- 2.12
- 0.43
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 17%of 946
Top 7%of 871
Bottom 18%of 867
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 1.58 | 1.42 | +11.3% |
| Feb 5, 2026 | 1.26 | 1.23 | +2.4% |
| Oct 30, 2025 | 1.08 | 1.52 | −28.9% |
| Apr 24, 2025 | 1.21 | 1.49 | −18.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
52No pass
Benjamin Graham
29No pass
Philip Fisher
62Pass
Peter Lynch
26No pass
Joel Greenblatt
25No pass
Charlie Munger
59No pass
Terry Smith
59No pass
Questions about Bristol-Myers Squibb Company Ce
Is Bristol-Myers Squibb Company Ce a good stock to buy?
A strong, very profitable business that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bristol-Myers Squibb Company Ce AI analysis
What does Bristol-Myers Squibb Company Ce do?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It is in Drug Manufacturers - General.
How has Bristol-Myers Squibb Company Ce stock done over the past year?
Up 327.4% over the past twelve months, to $0.12. It traded between $0.02 and $0.23 and is 47.0% below its high.
Who are Bristol-Myers Squibb Company Ce's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Bristol-Myers Squibb Company Ce's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.